Allergy/Imm

sponsor

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Kouiavskaia DV et al. - There were no significant changes in serum PSA level in any subject. No serious adverse events were observed. PSA: 154-163 is not an effective immunogen when given with Montanide ISA-51. The PSA: 154-163 peptide is poorly processed from endogenous PSA and therefore represents a cryptic epitope of PSA in HLA-A2 antigen-presenting cells.

Today in Hematology/Oncology...keeping you current

The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
Cancer Treatment Reviews, 12/04/09

IL-13 from Th2-type cells suppresses induction of antigen-specific Th1 immunity in a T-cell lymphoma
International Immunology, 12/03/09

Prioritization of cancer antigens: keeping the target in sight
Expert Review of Vaccines, 12/02/09